The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

In a recent study investigators established that extended dupilumab therapy-up to three years-is highly effective in the ...

The safety profile of Dupixent in adolescents with moderate-to-severe asthma contributed to the FDA's decision.

The Food and Drug Administration (FDA) has expanded the approval of Dupixent ® (dupilumab) to include add-on maintenance treatment of adolescent patients aged 12 to 17 years with inadequately ...

It was a busy week for the biotech sector with a lot of important data readouts at the European Society for Medical Oncology ...

nasal polyp size and sense of smell, while also reducing the need for systemic corticosteroids or surgery at 24 weeks compared to placebo. The approval is also supported by pharmacokinetic data ...

nasal polyp size, sense of smell, and reduced the need for systemic corticosteroids or surgery at 24 weeks compared to placebo. Dupixent's safety profile in adolescents was consistent with that ...

In some situations, a healthcare provider can make a nasal polyp diagnosis by visually examining the nasal passages using an otoscope (a simple lighted tool usually used to look inside the ears).

She was referred to the otolaryngology clinic with complaints of chronic nasal stuffiness, usually clear with episodes of purulent rhinorrhea, anosmia, and occasional headaches. Antibiotics were ...

Parents of children aged two and three are being urged to book them in for a nasal flu vaccine. NHS England will contact more than a million parents and carers from Tuesday to tell them the nasal ...